Efficacy of saffron as an adjunct treatment for unremitted depression in adults: a randomised, double-blind placebo-controlled study

Murdoch University0 个研究点目标入组 160 人开始时间: 2018年5月4日最近更新: 2019年9月30日

适应症

试验速览

暂无简介。

•1. Adults (male and female) aged between 18 and 65 years
•2. Currently taking a stable dose (at least 8 weeks) of a single pharmaceutical antidepressant (SSRI or SNRI)
•3. Despite antidepressant treatment, continues to suffer from mild-to-moderate depression as assessed by a validated measure
•4. Fluent in English
•5. Willing to provide a personally signed and dated informed consent form detailing all pertinent aspects of the trial.
•6. Willing and able to take prescribed placebo/saffron

•1. DSM-5 diagnoses other than major depression, including but not limited to bipolar disorder, anxiety disorders, schizophrenia, psycho-organic syndromes, eating disorders, substance abuse or dependence disorders.
•2. At significant risk of suicide or engaging in self-harm behaviours
•3. Pregnant women, women who are breastfeeding or women who intended to fall pregnant.
•4. Suffering from major medical illness, including neurodegenerative /neuroinflammatory disorders, such as Alzheimer’s disease, stroke, Parkinson’s disease or multiple sclerosis; autoimmune disorders, diabetes, inflammatory bowel disease, COPD, etc.
•5. Currently taking medications including, but not limited to glucocorticoids, antibiotics, and anticoagulant medications. Use of analgesics (once a week) or contraceptive pills are permissible.
•6. Currently taking saffron supplements and/or other specific herbal products, including omega-3 fatty acids.
•7. Greater than 10-year history of depression

发起方